Core Insights - Coeptis Therapeutics has secured five new clients with a total contract value of 450,000 from Managed Services Agreements valued at $1.25 million, highlighting the immediate market opportunity for its AI-driven marketing solutions [2] - The CEO of Coeptis expressed optimism about the early uptake of the NexGenAI platform, emphasizing its potential to enhance customer engagement and marketing strategies [3][5] Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [5] - The company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR T technology licensed from the University of Pittsburgh [5] Technology and Innovation - The NexGenAI Affiliates Network is designed to revolutionize marketing and business operations through AI-driven marketing software, robotic process automation, and data analytics [7] - Upcoming features of the NexGenAI platform include an AI Dialer Service, AI SMS Service, and advanced RPA Assistance, aimed at enhancing communication and operational efficiency [8] Market Trends - The integration of AI in marketing is transforming the industry by enabling businesses to personalize campaigns, optimize in real-time, and gain insights into consumer behavior [4] - As AI technology evolves, it is expected to play a crucial role in shaping various sectors and driving advancements in business practices [4]
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform